126 related articles for article (PubMed ID: 16037288)
1. Low-molecular weight advanced glycation end products: markers of tissue AGE accumulation and more?
Thomas MC; Forbes JM; MacIsaac R; Jerums G; Cooper ME
Ann N Y Acad Sci; 2005 Jun; 1043():644-54. PubMed ID: 16037288
[TBL] [Abstract][Full Text] [Related]
2. Low-molecular but not high-molecular advanced glycation end products (AGEs) are removed by high-flux dialysis.
Gerdemann A; Lemke HD; Nothdurft A; Heidland A; Münch G; Bahner U; Schinzel R
Clin Nephrol; 2000 Oct; 54(4):276-83. PubMed ID: 11076103
[TBL] [Abstract][Full Text] [Related]
3. The advanced glycation end product N(epsilon)-carboxymethyllysine is not a predictor of cardiovascular events and renal outcomes in patients with type 2 diabetic kidney disease and hypertension.
Busch M; Franke S; Wolf G; Brandstädt A; Ott U; Gerth J; Hunsicker LG; Stein G;
Am J Kidney Dis; 2006 Oct; 48(4):571-9. PubMed ID: 16997053
[TBL] [Abstract][Full Text] [Related]
4. In vitro-prepared advanced glycation end-products and the modulating potential of their low-molecular weight degradation products in IRPTC-A rat proximal-tubular derived kidney epithelial cell line.
Deuther-Conrad W; Franke S; Henle T; Sommer M; Stein G
Cell Mol Biol (Noisy-le-grand); 2001; 47 Online Pub():OL187-96. PubMed ID: 11936867
[TBL] [Abstract][Full Text] [Related]
5. From molecular footprints of disease to new therapeutic interventions in diabetic nephropathy.
Miyata T; Yamamoto M; Izuhara Y
Ann N Y Acad Sci; 2005 Jun; 1043():740-9. PubMed ID: 16037301
[TBL] [Abstract][Full Text] [Related]
6. Low-molecular-weight AGEs are associated with GFR and anemia in patients with type 2 diabetes.
Thomas MC; Tsalamandris C; MacIsaac R; Medley T; Kingwell B; Cooper ME; Jerums G
Kidney Int; 2004 Sep; 66(3):1167-72. PubMed ID: 15327413
[TBL] [Abstract][Full Text] [Related]
7. Plasma advanced glycation end products are decreased in obese children compared with lean controls.
Sebeková K; Somoza V; Jarcusková M; Heidland A; Podracká L
Int J Pediatr Obes; 2009; 4(2):112-8. PubMed ID: 18645732
[TBL] [Abstract][Full Text] [Related]
8. Identification of CML-modified proteins in hemofiltrate of diabetic patients by proteome analysis.
Schmitt S; Linder M; Ständker L; Hammes HP; Preissner KT
Exp Clin Endocrinol Diabetes; 2008 Jan; 116(1):26-34. PubMed ID: 17926233
[TBL] [Abstract][Full Text] [Related]
9. Advanced glycation endproducts in food and their effects on health.
Poulsen MW; Hedegaard RV; Andersen JM; de Courten B; Bügel S; Nielsen J; Skibsted LH; Dragsted LO
Food Chem Toxicol; 2013 Oct; 60():10-37. PubMed ID: 23867544
[TBL] [Abstract][Full Text] [Related]
10. Oral administration of AST-120 (Kremezin) is a promising therapeutic strategy for advanced glycation end product (AGE)-related disorders.
Yamagishi S; Nakamura K; Matsui T; Inoue H; Takeuchi M
Med Hypotheses; 2007; 69(3):666-8. PubMed ID: 17331665
[TBL] [Abstract][Full Text] [Related]
11. Low molecular weight advanced glycation end products predict mortality in asymptomatic patients receiving chronic haemodialysis.
Roberts MA; Thomas MC; Fernando D; Macmillan N; Power DA; Ierino FL
Nephrol Dial Transplant; 2006 Jun; 21(6):1611-7. PubMed ID: 16520354
[TBL] [Abstract][Full Text] [Related]
12. Quantitative screening of advanced glycation endproducts in cellular and extracellular proteins by tandem mass spectrometry.
Thornalley PJ; Battah S; Ahmed N; Karachalias N; Agalou S; Babaei-Jadidi R; Dawnay A
Biochem J; 2003 Nov; 375(Pt 3):581-92. PubMed ID: 12885296
[TBL] [Abstract][Full Text] [Related]
13. Accumulation of advanced glycation end products and chronic complications in ESRD treated by dialysis.
Meerwaldt R; Zeebregts CJ; Navis G; Hillebrands JL; Lefrandt JD; Smit AJ
Am J Kidney Dis; 2009 Jan; 53(1):138-50. PubMed ID: 19036487
[TBL] [Abstract][Full Text] [Related]
14. Short-term effects of dietary advanced glycation end products in rats.
Poulsen MW; Andersen JM; Hedegaard RV; Madsen AN; Krath BN; Monošík R; Bak MJ; Nielsen J; Holst B; Skibsted LH; Larsen LH; Dragsted LO
Br J Nutr; 2016 Feb; 115(4):629-36. PubMed ID: 26824730
[TBL] [Abstract][Full Text] [Related]
15. Characterization of advanced glycation end products: mass changes in correlation to side chain modifications.
Schmitt A; Gasic-Milenkovic J; Schmitt J
Anal Biochem; 2005 Nov; 346(1):101-6. PubMed ID: 16168380
[TBL] [Abstract][Full Text] [Related]
16. Regular moderate exercise reduces advanced glycation and ameliorates early diabetic nephropathy in obese Zucker rats.
Boor P; Celec P; Behuliak M; Grancic P; Kebis A; Kukan M; Pronayová N; Liptaj T; Ostendorf T; Sebeková K
Metabolism; 2009 Nov; 58(11):1669-77. PubMed ID: 19608208
[TBL] [Abstract][Full Text] [Related]
17. Autofluorescence characterization of advanced glycation end products of hemoglobin.
Vigneshwaran N; Bijukumar G; Karmakar N; Anand S; Misra A
Spectrochim Acta A Mol Biomol Spectrosc; 2005 Jan; 61(1-2):163-70. PubMed ID: 15556435
[TBL] [Abstract][Full Text] [Related]
18. Paraoxonase-1 concentrations in end-stage renal disease patients increase after hemodialysis: correlation with low molecular AGE adduct clearance.
Gugliucci A; Mehlhaff K; Kinugasa E; Ogata H; Hermo R; Schulze J; Kimura S
Clin Chim Acta; 2007 Feb; 377(1-2):213-20. PubMed ID: 17118352
[TBL] [Abstract][Full Text] [Related]
19. Depletion of reactive advanced glycation endproducts from diabetic uremic sera using a lysozyme-linked matrix.
Mitsuhashi T; Li YM; Fishbane S; Vlassara H
J Clin Invest; 1997 Aug; 100(4):847-54. PubMed ID: 9259584
[TBL] [Abstract][Full Text] [Related]
20. A novel advanced glycation index and its association with diabetes and microangiopathy.
Sampathkumar R; Balasubramanyam M; Rema M; Premanand C; Mohan V
Metabolism; 2005 Aug; 54(8):1002-7. PubMed ID: 16092048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
